---
schema_version: "secwatch.filing_event.v1"
accession: "0001104659-26-047335"
form_type: "8-K"
ticker: "CPIX"
cik: "0001087294"
company_name: "CUMBERLAND PHARMACEUTICALS INC"
filed_at: "2026-04-23T23:59:59+00:00"
generated_at: "2026-05-15T04:24:32.533267+00:00"
event_type: "m_and_a"
sentiment: "positive"
materiality_score: 0.85
calibrated_materiality_score: 0.85
confidence: "high"
source: SEC EDGAR
---

# Cumberland Pharma sells commercial products to Apotex for $100M, retains pipeline

## Summary
- Apotex acquires six FDA-approved brands (Acetadote, Caldolor, Kristalose, Sancuso, Vaprisol, Vibativ) for $100M cash.
- Cumberland retains ifetroban pipeline (DMD, SSc, IPF) and majority stake in CETI.
- Deal requires shareholder approval; directors & officers holding ≈41% of shares signed voting agreements to support.
- Either party may owe $4M termination fee under conditions; closing targeted by August 20, 2026.
- Board and financial advisor VelocityHealth opined $100M consideration fair and reasonable to Cumberland.

## SEC filing metadata
- accession: 0001104659-26-047335
- form_type: 8-K
- ticker: CPIX
- cik: 0001087294
- company_name: CUMBERLAND PHARMACEUTICALS INC
- filed_at: 2026-04-23T23:59:59+00:00
- event_type: m_and_a
- sentiment: positive
- materiality_score: 0.85
- calibrated_materiality_score: 0.85
- confidence: high
- sec_items: 1.01, 7.01, 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1087294/000110465926047335/0001104659-26-047335-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1087294/000110465926047335/tm2611622d1_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001104659-26-047335
- JSON: https://secwatch.observer/filing/0001104659-26-047335.json
- Plain text: https://secwatch.observer/filing/0001104659-26-047335.txt

## Source-grounded claims
- claim_id: 4ae37d7ca72657ef4362aec7c9559adb7810bc6c
  claim: CUMBERLAND PHARMACEUTICALS INC entered into Asset Purchase Agreement with Apotex Inc. valued at $100,000,000 (effective 2026-04-22).
  evidence_excerpt: On April 22, 2026, Cumberland Pharmaceuticals Inc. (the “ Company ” or “ Cumberland ”) entered into a strategic transaction (the “ Transaction ”) to integrate its commercial products with the U.S. branded business of an affiliate of Apotex Inc., a corporation incorporated under the laws of the Province of Ontario (“ Apotex ”), in exchange for $100,000,000 payable at the closing of the Transaction.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1087294/000110465926047335/0001104659-26-047335-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.